Disclosures for "Subgroup Analyses of Effect of Treatment With Levodopa Inhalation Powder (CVT-301) 84mg by Severity of OFF Symptoms in People with Parkinson’s Disease, as Assessed by the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III)")
-
Dr. Cohen has received personal compensation for serving as an employee of Acorda Therapeutics. Dr. Cohen has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for VBL Therapeutics. Dr. Cohen has stock in Acorda Therapeutics.
-
Ping Zhao has received personal compensation for serving as an employee of Acorda Therapeutics Inc. Ping Zhao has received stock or an ownership interest from Acorda Therapeutics Inc..
-
Richard Marini has received personal compensation for serving as an employee of Acorda Therapeutics. Richard Marini has stock in Acorda Therapeutics.
-
Burkhard Blank has received personal compensation for serving as an employee of Acorda Therapeutics. Burkhard Blank has received stock or an ownership interest from Acorda Therapeutics, Inc.
-
Donald Grosset has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Glasgow Memory Clinic. Donald Grosset has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Donald Grosset has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AbbVie. Donald Grosset has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Britannia. Donald Grosset has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GE Healthcare. The institution of Donald Grosset has received research support from Parkinson's UK. Donald Grosset has received personal compensation in the range of $10,000-$49,999 for serving as a Clinical Director Excellence Network with Parkinson's UK.